Malaria Vaccines Market Size, Share, Trends, Industry Analysis Report: By Vaccine Type, Administration Route (Subcutaneous and Intramuscular), Target Population, Immunization Schedule, Development Stage, and Region (North America, Europe, Asia Pacific, La

The global malaria vaccines market size is expected to reach USD 1,619.87 million by 2034, according to a new study by Polaris Market Research. The report “Malaria Vaccines Market Size, Share, Trends, Industry Analysis Report: By Vaccine Type, Administration Route (Subcutaneous and Intramuscular), Target Population, Immunization Schedule, Development Stage, and Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) – Market Forecast, 2025–2034” gives a detailed insight into current market dynamics and provides analysis on future market growth.

Malaria is a serious, life-threatening disease caused by Plasmodium parasite, which is transmitted from human to human by the bite of infected mosquitoes. This mosquito-borne illness causes severe disease in kids and adults. Pregnant women and children are particularly vulnerable to the fever caused by malaria. Various precautions to control the disease include the use of insect nets and spraying of pesticides. However, current research studies have shown that insects are immune to pesticides, pesticides have harmful effects on human beings, and malaria fever is becoming immune to medications. In response to these challenges, researchers and pharmaceutical companies have been working on the development of malaria vaccines as an alternative method of prevention.

Several factors, such as the rising incidence of malaria worldwide and the introduction of low-cost malaria vaccines by pharma companies globally, are driving the malaria vaccines market growth. Rising awareness about the disease’s consequences and ongoing research and development (R&D) initiatives are further supporting the market development.

Growing efforts by government and private organizations to address the issues of weak supply chains and distribution networks in some malaria-endemic developing countries are expected to boost the adoption of malaria vaccines. Rising inoculation programs and emphasis on the development of innovative vaccine technologies are expected to provide several malaria vaccines market opportunities in the coming years.

Key Highlights of Malaria Vaccines Market Report

Based on vaccine type, the RTS,S/AS01 segment held the largest share of the malaria vaccines market revenue in 2024, owing to the extensive clinical research and trials demonstrating the efficacy of RTS, S/AS01 vaccines, and their rollout in various African countries.

By administration route, the intramuscular segment led the malaria vaccines market share in 2024 as intramuscular is the most widely used route for administrating malaria vaccines, including R21/Matrix-M and RTS,S/AS01.

North America led the market for malaria vaccines in 2024, driven by the strong presence of leading pharma companies with significant investments in malaria vaccine development programs and the introduction of favorable government regulations supporting malaria vaccine R&D initiatives.

The Middle East & Africa malaria vaccines market is projected to witness a significant CAGR from 2025 to 2034, driven by the rising focus on improving healthcare infrastructure and enhanced collaborations between government and private organizations to develop cost-effective malaria vaccines.

Instituto Butantan, Merck, PATH, GSK, Vaxart, Biovac, Pfizer, Inovio Pharmaceuticals, Bharat Biotech, University of Oxford, Intellia Therapeutics, Johnson & Johnson, Sanaria, and Takeda Pharmaceutical Company are a few of the key players in the market.

Polaris Market Research has segmented the malaria vaccines market research report on the basis of vaccine type, administration route, target population, immunization schedule, development stage, and region:

By Vaccine Type Outlook (Revenue – USD Million, 2020–2034)

PfSPZ

RTS,S/AS01

R21/Matrix-M

By Administration Route Outlook (Revenue – USD Million, 2020–2034)

Subcutaneous

Intramuscular

By Target Population Outlook (Revenue – USD Million, 2020–2034)

Travelers to Endemic Areas

Pregnant Women

Children under 5 Years

By Immunization Schedule Outlook (Revenue – USD Million, 2020–2034)

Single Dose

Multi-Dose

Booster Doses

By Development Stage Outlook (Revenue – USD Million, 2020–2034)

Preclinical

Clinical Trials

By Regional Outlook (Revenue – USD Million, 2020–2034)

North America

• US
• Canada

• Germany
• France
• UK
• Italy
• Spain
• Netherlands
• Russia
• Rest of Europe

• China
• Japan
• India
• Malaysia
• South Korea
• Indonesia
• Australia
• Rest of Asia Pacific

• Saudi Arabia
• UAE
• Israel
• South Africa
• Rest of Middle East & Africa

• Mexico
• Brazil
• Argentina
• Rest of Latin America